News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Jamie E Chaft, MD

Articles by Jamie E Chaft, MD

Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 28th 2023

Conclusion of the discussion and award presentation.

Optimal Approach for PD-L1 >50%

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 21st 2023

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

Treatment for Borderline Resectable Patients With NSCLC

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 21st 2023

Discussion on the treatment for borderline resectable patients with NSCLC.

Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 14th 2023

Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.

Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 14th 2023

EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.

Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 7th 2023

Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer

Introduction of the Debate Between Jets v. Giants

ByDeborah Doroshow, MD,Neel Chudgar, MD,Vamsidhar Velcheti, MD,Daniel R. Gomez, MD,Jamie E Chaft, MD,Fred R. Hirsch, MD, PhD,Mark G. Kris, MD

December 7th 2023

An outline of the debate, the speakers, and the basic guidelines to support the program.

Latest Updated Articles

Trending on CancerNetwork

Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC

Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC

Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups

Lenvatinib/Everolimus Beats Cabozantinib in Phase 2 RCC Study

Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC

© 2025 MJH Life Sciences^®

All rights reserved.